money moves

Houston venture capital group leads Austin-based energy tech company's $5M series A

Cottonwood Venture Partners has announced its latest investment. Photo via huvrdata.com

Houston-based Cottonwood Venture Partners has announced the closing of an Austin-based software solutions round that it led.

Founded in 2014, HUVRdata Inc. is a data analytics company focusing on the energy industry. The startup announced the closing of its $5 million series A round this week. According to a press release, the company will use these funds on product development to support its growing customer base.

"HUVR was built alongside our customers' operations teams — designed from the ground up to be simple to use, flexible to implement, and valuable from day one," says Bob Baughman, HUVR co-founder and CEO, in a news release. "We are the first to build an open platform where asset inspection data can be aggregated with valuable and configurable reporting and analytics. The vision was to have asset owners own their own asset data, and, more importantly, to use their data to make business decisions. The results are significant efficiency gains and millions of dollars in savings."

HUVR, the latest software company to join CVP's portfolio, gives industrial asset owners the tools to aggregate and analyze all aspects of complex asset inspection data — like the ability to visualize trends across drone fleets, site, and individual assets.

"The volume of industrial inspection data is growing exponentially," says Ryan Gurney, managing partner of CVP, in the release. "Operators are deploying new inspection tools to inspect a growing, and aging, asset base. The tools and processes of the past are simply unable to handle the data. The HUVR platform allows its customers to aggregate their vast amounts of inspection data – more importantly, HUVR is enabling its customers to gain insights from that data. We are delighted to partner with the HUVR team in the next chapter of their growth."

It's not the first time the Austin company has received funding from Houston. According to a release from HUVR in August 2015, the startup received $2 million in angel investment from Houston Angel Network, Houston-based Texas HALO fund, and Austin-based Central Texas Angel Network.

Trending News

Building Houston

 
 

A new report says Houston “is poised for further growth” in life sciences. Photo via Getty Images

Houston is receiving more kudos for its robust life sciences sector.

Bayou City lands at No. 13 in JLL’s 2022 ranking of the country’s top 15 metro areas for life sciences. JLL says Houston “is poised for further growth” in life sciences.

Here’s how Houston fares in each of the ranking’s three categories:

  • No. 12 for supply of life sciences-oriented commercial real estate
  • No. 14 for access to life sciences talent
  • No. 15 for life sciences grant funding and venture capital

Earlier this year, Houston scored a 13th-place ranking on a list released by JLL competitor CBRE of the country’s top 25 life sciences markets. Meanwhile, commercial real estate platform CommercialCafe recently placed Houston at No. 10 among the top U.S. metros for life sciences.

JLL applauds Houston for strong growth in the amount of life sciences talent along with “an impressive base of research institutions and medical centers.” But it faults Houston for limited VC interest in life sciences startups and a small inventory of lab space.

“Houston is getting a boost [in life sciences] from the growing Texas Medical Center and an influx of venture capital earmarked for life sciences research,” the Greater Houston Partnership recently noted.

Boston appears at No. 1 in this year’s JLL ranking, followed by the San Francisco Bay Area, San Diego, Washington, D.C./Baltimore, and Philadelphia.

Last year’s JLL list included only 10 life sciences markets; Houston wasn’t among them.

“The long-term potential of the sector remains materially unchanged since 2021,” Travis McCready, head of life sciences for JLL’s Americas markets, says in a news release.

“Innovation is happening at a more rapid pace than ever before, the fruits of research into cell and gene therapy are just now being harvested, and revenue growth has taken off in the past five years as the sector becomes larger, an atypical growth track.”

Trending News